Hangzhou Tigermed Consulting (300347) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.019x

Based on the latest financial reports, Hangzhou Tigermed Consulting (300347) has a cash flow conversion efficiency ratio of 0.019x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥475.40 Million ≈ $69.57 Million USD) by net assets (CN¥24.71 Billion ≈ $3.62 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Hangzhou Tigermed Consulting (300347) balance sheet quality index to measure how much of total assets are equity-financed.

Hangzhou Tigermed Consulting - Cash Flow Conversion Efficiency Trend (2009–2025)

This chart illustrates how Hangzhou Tigermed Consulting's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Hangzhou Tigermed Consulting's earnings quality to evaluate the quality of earnings relative to operating cash generation.

Hangzhou Tigermed Consulting Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Hangzhou Tigermed Consulting ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
TCL Zhonghuan Renewable Energy Technology Co Ltd SHE:002129	0.024x
Dianthus Therapeutics Inc. NASDAQ:DNTH	-0.024x
Kanzhun Ltd ADR NASDAQ:BZ	0.066x
Jiangsu Leadmicro Nano Technology Co. Ltd. A SHG:688147	N/A
VEND MARKETPLACES ASA OL:VEND	0.027x
Chewy Inc NYSE:CHWY	0.256x
Pampa Energia SA BA:PAMP	-0.061x
United Plantations Bhd KLSE:2089	0.304x

Annual Cash Flow Conversion Efficiency for Hangzhou Tigermed Consulting (2009–2025)

The table below shows the annual cash flow conversion efficiency of Hangzhou Tigermed Consulting from 2009 to 2025. For the full company profile with market capitalisation and key ratios, see 300347 company net worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CN¥24.26 Billion ≈ $3.55 Billion	CN¥1.12 Billion ≈ $163.61 Million	0.046x	+1.12%
2024-12-31	CN¥24.06 Billion ≈ $3.52 Billion	CN¥1.10 Billion ≈ $160.53 Million	0.046x	-3.10%
2023-12-31	CN¥24.45 Billion ≈ $3.58 Billion	CN¥1.15 Billion ≈ $168.35 Million	0.047x	-21.40%
2022-12-31	CN¥22.68 Billion ≈ $3.32 Billion	CN¥1.36 Billion ≈ $198.65 Million	0.060x	-13.38%
2021-12-31	CN¥20.61 Billion ≈ $3.02 Billion	CN¥1.42 Billion ≈ $208.35 Million	0.069x	+23.56%
2020-12-31	CN¥17.86 Billion ≈ $2.61 Billion	CN¥998.68 Million ≈ $146.14 Million	0.056x	-41.47%
2019-12-31	CN¥5.52 Billion ≈ $807.94 Million	CN¥527.56 Million ≈ $77.20 Million	0.096x	-40.13%
2018-12-31	CN¥3.27 Billion ≈ $478.82 Million	CN¥522.24 Million ≈ $76.42 Million	0.160x	+41.95%
2017-12-31	CN¥2.80 Billion ≈ $409.92 Million	CN¥314.97 Million ≈ $46.09 Million	0.112x	+7.79%
2016-12-31	CN¥1.84 Billion ≈ $269.22 Million	CN¥191.91 Million ≈ $28.08 Million	0.104x	-40.14%
2015-12-31	CN¥1.07 Billion ≈ $155.98 Million	CN¥185.73 Million ≈ $27.18 Million	0.174x	+265.93%
2014-12-31	CN¥916.90 Million ≈ $134.17 Million	CN¥43.66 Million ≈ $6.39 Million	0.048x	-53.36%
2013-12-31	CN¥755.14 Million ≈ $110.50 Million	CN¥77.10 Million ≈ $11.28 Million	0.102x	+373.15%
2012-12-31	CN¥694.32 Million ≈ $101.60 Million	CN¥14.98 Million ≈ $2.19 Million	0.022x	-91.86%
2011-12-31	CN¥146.03 Million ≈ $21.37 Million	CN¥38.69 Million ≈ $5.66 Million	0.265x	-4.53%
2010-12-31	CN¥95.79 Million ≈ $14.02 Million	CN¥26.59 Million ≈ $3.89 Million	0.278x	-44.03%
2009-12-31	CN¥44.26 Million ≈ $6.48 Million	CN¥21.95 Million ≈ $3.21 Million	0.496x	--

About Hangzhou Tigermed Consulting

SHE:300347 China Diagnostics & Research

Market Cap

$5.36 Billion

CN¥36.62 Billion CNY

Market Cap Rank

#3388 Global

#452 in China

Share Price

CN¥49.63

Change (1 day)

-0.72%

52-Week Range

CN¥36.17 - CN¥69.86

All Time High

CN¥43083.62